Reviva Pharmaceuticals Holdings (RVPH) Price & Analysis

Compare

1,173 Followers

RVPH Stock Chart & Stats

$0.26

-$0.09(-4.50%)

At close: Jan 08 4:00 PM EST

$0.26

-$0.09(-4.50%)

Day’s Range― - ―

52-Week Range$0.25 - $2.05

Previous CloseN/A

Volume1.63M

Average Volume (3M)14.40M

Market Cap

$30.33M

Enterprise Value$4.30M

Total Cash (Recent Filing)$13.18M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.09

Next Earnings

Mar 23, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding115,058,620

10 Day Avg. Volume22,198,486

30 Day Avg. Volume14,401,288

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)73.84

Price to Sales (P/S)0.00

P/FCF Ratio-1.79

Enterprise Value/Market Cap0.14

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.19

Forecast

1Y Price Target

$5.10

Price Target Upside1861.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentPlanned initiation of the RECOVER-2 Phase 3 trial pending sufficient financing would advance the pivotal program for brilaroxazine toward registration.

Efficacy And SafetyOne-year open-label data demonstrating sustained improvements in core schizophrenia measures and minimal movement-related side effects supports a favorable benefit-risk profile for brilaroxazine.

Regulatory And Intellectual PropertyOrphan Drug Designation for idiopathic pulmonary fibrosis and a European patent for a lung fibrosis use provide regulatory exclusivity and intellectual property protection for potential additional indications.

Bears Say

Development Timeline RiskA mandated additional pivotal study increases the likelihood that pivotal development cannot be completed in a timely manner, extending the timeline to commercialization.

Financing And Execution RiskThe need for another large-scale Phase 3 trial raises capital requirements and may force additional financing or partnerships, which could dilute shareholders or complicate execution.

Regulatory RequirementFDA written feedback recommending a second Phase 3 trial creates a confirmatory registrational requirement that could delay the approval pathway for schizophrenia.

Reviva Pharmaceuticals Holdings News

Vanguard Total Stock Market ETF (VTI) Daily Update—2/13/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.38% in...

7h ago

IMA

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/12/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.24% in...

1d ago

CLB

IMA

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/11/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.56% in...

2d ago

CLB

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/10/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up 0.11% in...

3d ago

CLB

IMA

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—2/9/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.16% in...

4d ago

CLB

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Regencell Bioscience Holdings Ltd...

10d ago

BRR

NFE

Vanguard Total Stock Market ETF (VTI) Daily Update—1/29/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up by 0.15%...

15d ago

CLB

IMA

Vanguard Total Stock Market ETF (VTI) Daily Update—1/28/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is up by 0.27%...

16d ago

CLB

IMA

Reviva Pharmaceuticals Granted Nasdaq Extension to Regain Compliance

Reviva Pharmaceuticals Holdings ( ($RVPH) ) has shared an announcement. Reviva Pharmaceuticals Holdings, which is listed on the...

21d ago

RVPH

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/13/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.067% in...

1M ago

RKT

VTI

Reviva announces publication on clinical vocal biomarker data from RECOVER trial

Reviva Pharmaceuticals (RVPH) Holdings announced the publication, in the peer-reviewed journal Biological Psychiatry, of an article entitled A...

1M ago

RVPH

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/8/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.12% in...

1M ago

VTI

AAPL

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: PharmaCyte Biotech (PMCB) 96.86%...

2M ago

BTQ

BILI

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Infosys (INFY) 47.38% +29.74,...

2M ago

NNE

WWR

RVPH FAQ

What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?

Reviva Pharmaceuticals Holdings lowest stock price was $0.25 and its highest was $2.05 in the past 12 months.

What is Reviva Pharmaceuticals Holdings’s market cap?

Reviva Pharmaceuticals Holdings’s market cap is $30.33M.

When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?

Reviva Pharmaceuticals Holdings’s upcoming earnings report date is Mar 23, 2026 which is in 38 days.

How were Reviva Pharmaceuticals Holdings’s earnings last quarter?

Reviva Pharmaceuticals Holdings released its earnings results on Nov 13, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.095 by $0.035.

Is Reviva Pharmaceuticals Holdings overvalued?

According to Wall Street analysts Reviva Pharmaceuticals Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Reviva Pharmaceuticals Holdings pay dividends?

Reviva Pharmaceuticals Holdings does not currently pay dividends.

What is Reviva Pharmaceuticals Holdings’s EPS estimate?

Reviva Pharmaceuticals Holdings’s EPS estimate is -0.05.

How many shares outstanding does Reviva Pharmaceuticals Holdings have?

Reviva Pharmaceuticals Holdings has 115,058,620 shares outstanding.

What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?

Reviva Pharmaceuticals Holdings reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.095. Following the earnings report the stock price went down -7.407%.

Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?

Currently, no hedge funds are holding shares in RVPH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Reviva Pharmaceuticals Holdings Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

44.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Reviva Pharmaceuticals Holdings

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

Reviva Pharmaceuticals Holdings (RVPH) Earnings & Revenues

Historic Earnings Reports

RVPH Stock 12 Month Forecast

Average Price Target

$5.10

▲(1861.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","17":"$17","-1":"-$1","3.5":"$3.5","12.5":"$12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3.5,8,12.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.292,1.5003076923076923,2.7086153846153844,3.9169230769230765,5.125230769230769,6.333538461538462,7.541846153846153,8.750153846153847,9.958461538461538,11.16676923076923,12.375076923076923,13.583384615384615,14.791692307692307,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.292,0.6618461538461538,1.0316923076923077,1.4015384615384614,1.7713846153846153,2.141230769230769,2.5110769230769225,2.8809230769230765,3.2507692307692304,3.6206153846153843,3.9904615384615383,4.360307692307692,4.730153846153845,{"y":5.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.292,0.3849230769230769,0.4778461538461538,0.5707692307692307,0.6636923076923076,0.7566153846153845,0.8495384615384616,0.9424615384615385,1.0353846153846153,1.1283076923076922,1.2212307692307691,1.314153846153846,1.4070769230769231,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.98,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.292,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >